Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatment
Autore:
Walker, JR; Van Ameringen, MA; Swinson, R; Bowen, RC; Chokka, PR; Goldner, E; Johnston, DC; Lavallie, YJ; Nandy, S; Pecknold, JC; Hadrava, V; Lane, RM;
Indirizzi:
Sertraline Social Phobia Study Grp, New York, NY USA Sertraline Social Phobia Study Grp New York NY USA Grp, New York, NY USA Pfizer Inc, Pfizer Pharmaceut Grp, New York, NY USA Pfizer Inc New York NY USA Inc, Pfizer Pharmaceut Grp, New York, NY USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 6, volume: 20, anno: 2000,
pagine: 636 - 644
SICI:
0271-0749(200012)20:6<636:PORIGS>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; ANXIETY DISORDER; CONTROLLED TRIAL; PLACEBO; SCALE; DISCONTINUATION; MOCLOBEMIDE; PHENELZINE; PHARMACOTHERAPY; FLUVOXAMINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Walker, JR St Boniface Gen Hosp, Anxiety Disorders Program, M5-409 Tache Ave, Winnipeg, MB R2H 2A6, Canada St Boniface Gen Hosp M5-409 Tache Ave Winnipeg MB Canada R2H 2A6
Citazione:
J.R. Walker et al., "Prevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatment", J CL PSYCH, 20(6), 2000, pp. 636-644

Abstract

The aim of this study was to evaluate the efficacy, tolerability, and effects on quality of life of sertraline, a selective serotonin reuptake inhibitor, in the prevention of relapse of generalized social phobia. Fifty adultoutpatients with generalized social phobia wine were rated much or very much improved on the Clinical Global Impression Scale of Improvement (CGI-I) after 20 weeks of sertraline treatment (50-200 mg/day) were randomly assigned in a one-to-one ratio to either continue double-blind treatment with sertraline or immediately switch to placebo for another 24 weeks. The initial 20-week study was placebo-controlled, and 15 responders to placebo also continued to receive double-blind placebo treatment in the continuation study. Eighty-eight percent of patients in the sertraline-continuation group and only 40% of patients in the placebo-switch and placebo-responder groups completed the study. In intent-to-treat endpoint analyses, 1 (4%) of 25 patients in the sertraline-continuation group and 9 (36%) of 25 patients in the placebo-switch group had relapsed at study endpoint (chi (2) = 8.0, Fisher exact test, p = 0.01). The relative risk (hazards ratio) for relapse associated with placebo-switch relative to sertraline-continuation treatment was 10.2 (95% confidence interval, 1.3-80.7). Mean CGI-Severity, Marks Fear Questionnaire (MFQ) Social Phobia subscale, and Duke Brief Social Phobia Scale (BSPS) total scores were seduced by 0.07, 0.34, and 1.86 in the Sertraline-Continuation group and increased by 0.88, 4.09, and 5.99 in the Placebo-Switch group (all F > 5.3, p < 0.03), respectively. CGI-Severity, MFQ Social Phobia subscale, and BSPS scores also increased in the Placebo-Responder group. Discontinuations because of lack of efficacy were 4% in the sertraline-continuation group, 28% in the placebo-switch group (<chi>(2) = 5.36, Fisher exact test, p = 0.049), relative to sertraline, and 27% in the placebo-responder group. Sertraline was effective in preventing relapse of generalized social phobia. Future research should assess whether improvements may be maintained or further increased by longer periods of treatment or through the addition of cognitive-behavioral techniques.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 02:47:03